Non-Small Cell Lung Cancer (NSCLC) - Metastatic

IRB# 18084 S1609 (DART): Molecular Analysis for Therapy Choice (MATCH)

IRB# 19992 MATCH: Molecular Analysis for Therapy Choice (MATCH)

IRB# 21325: RGX-104

1st line

Squamous

Non-squamous

IRB# 21821 CodeBreak 101: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetic, and Efficacy of AMG 510 (INN Sotorasib) in Combination with Palbociclib in Subjects with Advanced Solid Tumors with KRAS p.G12C mutation (CodeBreak 101 Subprotocol J)

IRB# 23575 NIT-119: A multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-17 (efinepatkin alfa) in combination with atezolizumab in subjects with previously untreated, PD-L1-expressing, locally advanced or metastatic Non-Small Cell Lung Cancer

IRB# 23575 NIT-119: A multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-17 (efinepatkin alfa) in combination with atezolizumab in subjects with previously untreated, PD-L1-expressing, locally advanced or metastatic Non-Small Cell Lung Cancer

IRB# 23462 TROPION-LUNGS: Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-Small Cell Lung Cancer with Actionable Genomic Alterations and Progressed On or After Applicable Targeted Therapy and Platinum-based Chemotherapy

IRB# 21821 CodeBreak 101: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetic, and Efficacy of AMG 510 (INN Sotorasib) in Combination with Palbociclib in Subjects with Advanced Solid Tumors with KRAS p.G12C mutation (CodeBreak 101 Subprotocol J)

IRB# 21821 CodeBreak 101: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetic, and Efficacy of AMG 510 (INN Sotorasib) in Combination with Palbociclib in Subjects with Advanced Solid Tumors with KRAS p.G12C mutation (CodeBreak 101 Subprotocol J)

IRB# 21821 CodeBreak 101: A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

IRB# 22772 S1900E: A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

IRB# 21770 EAS191: A Randomized Phase II Trial of Cabozantinib and Cabozantinib plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC

IRB# 23051 SAPPHIRE: A Randomized Phase 3 Study of Sitratavatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

IRB# 22874 Iovance TIL: A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer

http://www.ohsu.edu/research/rda/so/knight.php

11.15.2021